EFPIA sees RWE as key to future healthcare decision-making

24 March 2025

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has published a paper on its vision for the role and use of real-world evidence (RWE) in decision-making.

This piece, called Harnessing RWE to transform Healthcare Decision-Making in Europe, considers the value of this data for the insights that it offers from everyday clinical practice.

According to EFPIA, RWE complements clinical trial data, offering a holistic understanding of treatment effectiveness, safety and value in diverse, real-world populations. This supports the discovery and development of innovative new medicines, helping to understand how medicines work in the real world.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK